Protagenic Therapeutics delays annual report filing, seeks extra time to complete audit
Protagenic Therapeutics, Inc. PTIX | 0.00 |
- Protagenic Therapeutics filed a Form 12b-25 to delay its Form 10-K for the year ended March 31, 2026.
- Filing delay tied to extra time needed to complete the audit of consolidated financial statements.
- Audit work extended by complex accounting tied to a business combination completed during the fiscal year.
- Expects to file the Form 10-K within the 15-calendar-day extension period under Rule 12b-25.
- Late notice indicated no expected significant change in results versus the prior-year period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031235), on June 30, 2026, and is solely responsible for the information contained therein.
